Logo
DeutschClear Cookie - decide language by browser settings
Eisele, Simon (2009): Bestimmung der Wirksamkeit eines inaktivierten One-Shot Impfstoffes bei Ferkeln in der 1. oder 3. Lebenswoche mit Porcilis® PCV gegen das porcine Circovirus Typ 2 (PCV2) in zwei süddeutschen Betrieben. Dissertation, LMU München: Faculty of Veterinary Medicine
[img]
Preview
PDF
Eisele_Simon.pdf

965Kb

Abstract

Efficacy of an inactivated one-shot piglet vaccine at either one or three weeks of age with Porcilis® PCV against porcine circovirus type 2 (PCV2) at two farms in southern Germany

Abstract

The goal of this study was to determine the efficacy of piglet vaccine with Porcilis® PCV administered at different times when compared to the placebo group receiving Diluvac® Forte. Two farms were selected where PMWS was diagnosed based on clinical symptoms, pathology and serology. A total of 627 piglets (209 per group) were used in this random blinded study. Group A animals were vaccinated in the third week of life, group C piglets in the first week and group B animals received a placebo. Parameters used to assess vaccine efficacy were average daily weight gain (ADWG), mortality, health status and the treatment index. Local reactions due to the vaccination were considered in order to asses the vaccine compatibility. Blood samples were taken in regular intervals from 34 animals per group and antibody levels were estimated using ELISA and antigen determination by qPCR. Both vaccine groups showed considerably improved ADWG although even better growth performance would have probably been achieved when vaccinated and non-vaccinated animals were separately housed in comparison to the group B placebos. Furthermore a significant decrease during the fattening period could be observed in both vaccine groups compared to the group B placebos. A significant reduction in mortality in both finishing farms was observed due to continued vaccination in the third week of life after the study began. Generally, the animals exhibited a favourable health status. Clinical examinations showed that the animals of the placebo group B in farm G had significantly higher score values in the categories lameness and body condition during the finishing period in comparison to both vaccine groups. An analysis of the treatment index documented the most individual treatment in the placebo group B. Only few local reactions occurred from the vaccination. The vaccination in the third week of life (group A) produced a very strong immune response. This led to a clear reduction in viremia during field infection with PCV2. With the aid of serological and molecular biological results from the placebo group B, it was possible to determine that the infection with PCV2 occurred in the nursery period. A considerable rise in the PCV2-antibodies was seen because of the viremia in placebo group B. The viremia was not prevented in all animals from group C. High maternal antibodies in individual piglets appear to interfere with the vaccination done in the first week of life in group C. This study reaffirmed the detection of vaccine induced antibodies against PCV2 using INGEZIM lgG/lgM ELISA. In order to identify the optimal time for vaccination, the determination of the PCV2 infection time by INGEZIM lgG/lgM ELISA and qPCR including antibody titre of the suckling piglet with ELISA appears to be invaluable. A field infection occurred in both farms whereas this led to noticeable effects early in the nursery period. The vaccination with Porcilis® PCV at both vaccine times emerged to be very effective. The present study proves that vaccination in the third week of life is most worthwhile since in addition to improved ADWG, reduced mortality and improved health status, a noticeable reduction in viremia after PCV2 field infection was also evident.